FLOW Trial Fortifies Semaglutide's Role in Chronic Kidney Disease and Type 2 Diabetes
HCPLive
MAY 24, 2024
Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.
Let's personalize your content